Clinical Trial Update: A Monocentric Study to Investigate a New Low Dose Oral Gut Cleansing Solution [Phase 2]

View source ↗

Summary

A Phase 2 monocentric trial sponsored by Norgine evaluating a new low-dose oral gut cleansing solution in colorectal cancer. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Low-dose oral gut cleansing solution

Snippet

Sponsor: Norgine | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED